Radiotherapy/Radiation / Dose Cancer Research Results

Rad, Radiotherapy/Radiation: Click to Expand ⟱
Features:
Treatment of disease with radiation, especially by selective irradiation with x-rays or other ionizing radiation and by ingestion of radioisotopes.

Radiosensitizer
Atorvaqone, (mitochondria inhibitor) decrease O2 consumption making more O2 available as a radiosensitizer.
-Hypoxia (low oxygen levels) within tumors is a major cause of resistance to radiotherapy


Dose, Dosage: Click to Expand ⟱
Source:
Type:
Drug dosage vs efficacy, and actual dosage number of research papers.
Scientific Papers found: Click to Expand⟱
4400- AgNPs,  Rad,    Differential cytotoxic and radiosensitizing effects of silver nanoparticles on triple-negative breast cancer and non-triple-negative breast cells
- in-vitro, BC, MCF7 - in-vitro, Nor, MCF10 - in-vitro, BC, MDA-MB-231 - in-vitro, BC, BT549 - in-vivo, BC, MDA-MB-231
ROS↑, DNAdam↑, selectivity↑, TumCG↓, RadioS↑, Dose↝, selectivity↑, other↝, eff↓, eff↑, γH2AX↑, Dose↓, eff↑,
5367- AV,  Rad,    Aloe vera for prevention of radiation-induced dermatitis: a self-controlled clinical trial
- Trial, Var, NA
radioP↑, Dose↝, eff↑,
2481- Ba,  Rad,    Radiotherapy Increases 12-LOX and CCL5 Levels in Esophageal Cancer Cells and Promotes Cancer Metastasis via THP-1-Derived Macrophages
- in-vitro, ESCC, Eca109 - in-vitro, ESCC, KYSE150
12LOX↓, RadioS↑, Dose↝, RANTES↓, MCP1/CCL2↓,
5741- Buty,  Rad,    Microencapsulated Sodium Butyrate in the Prevention of Acute Radiotherapy Proctitis: Single-Center Prospective Study
- in-vivo, Pca, NA
Dose↝, radioP↑, Pain↓,
1980- CUR,  Rad,    Thioredoxin reductase-1 (TxnRd1) mediates curcumin-induced radiosensitization of squamous carcinoma cells
- in-vitro, Cerv, HeLa - in-vitro, Laryn, FaDu
selectivity↑, RadioS↑, TrxR↓, ROS↑, ERK↑, Dose∅, cl‑PARP↑,
7305- GoldNP,  Rad,    The use of gold nanoparticles to enhance radiotherapy in mice
- in-vivo, Var, NA
Dose↝, selectivity↑, toxicity↝, RadioS↑,
3152- H2,  VitC,  Rad,    Hydrogen and Vitamin C Combination Therapy: A Novel Method of Radioprotection
- in-vitro, Nor, HUVECs - in-vivo, NA, NA
AntiTum↑, OS↑, QoL↑, TumVol↓, radioP↑, Dose↑, Dose↝, eff↑,
7481- H2,  Rad,    Clinical Efficacy of Hydrogen Therapy on Acute Radiation Enteritis and Inflammatory Response in Patients with Cervical Cancer Undergoing Concurrent Chemoradiation Therapy
- Trial, Var, NA
Dose↝, CRP↓, NLR↓, IL6↓, AntiTum∅, *toxicity↓, Inflam↓, radioP↑, *IBI↑, *ROS↓,
7577- HPT,  Rad,    Randomized trial of hyperthermia and radiation for superficial tumors
- Trial, Var, NA
RadioS↑, eff↑, Dose↝,
7651- HPT,  Rad,    Hyperthermia inhibits homologous recombination repair and sensitizes cells to ionizing radiation in a time- and temperature-dependent manner
- in-vitro, Var, NA
RadioS↑, DNArepair↓, Dose↑,
7649- HPT,  Rad,    A pilot study of the effects of mild systemic heating on human head and neck tumour xenografts: Analysis of tumour perfusion, interstitial fluid pressure, hypoxia and efficacy of radiation therapy
- in-vivo, Laryn, FaDu
Dose↝, BloodF↑, Hypoxia↓, RadioS?,
7572- HPT,  Rad,    The effect of thermal dose on hyperthermia-mediated inhibition of DNA repair through homologous recombination
- in-vitro, Cerv, HeLa - in-vitro, Laryn, FaDu
RadioS↑, TumCD↑, BRCA2↓, Dose↝, BloodF↑, ROS↑, Imm↑,
7621- HPT,  Rad,    Clinical effectiveness of combined whole body hyperthermia and external beam radiation therapy (EBRT) versus EBRT alone in patients with painful bony metastases: A phase III clinical trial study
- Trial, Pca, NA - Trial, BC, NA
Pain↓, Dose↝, CR↑,
7599- HPT,  Rad,    Recent development on hyperthermia: An effective cotreatment improving radiotherapy outcome
- Review, Var, NA
NA↑, RadioS↑, DNArepair↓, Hypoxia↓, EPR↑, LC↑, OS↑, *toxicity↓, Dose↝, BloodF↑, pH↝, Imm↑, HSP70/HSPA5↑,
7575- HPT,  Rad,  Chemo,  immuno,    From Localized Mild Hyperthermia to Improved Tumor Oxygenation: Physiological Mechanisms Critically Involved in Oncologic Thermo-Radio-Immunotherapy
RadioS↑, ChemoSen↑, Imm↑, BloodF↑, Hypoxia↓, Dose↝, DNArepair↓, e-pH↓,
5969- Rad,  CET,    Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival
- Trial, HNSCC, NA
Dose↝, radioP↑, OS↑,
3012- RosA,  Rad,    Rosmarinic Acid Prevents Radiation-Induced Pulmonary Fibrosis Through Attenuation of ROSMYPT1TGFβ1 Signaling Via miR-19b-3p
- in-vitro, Nor, IMR90
*Inflam↓, *ROS↓, *p‑NF-kB↓, *Rho↓, *ROCK1↓, *radioP↑, *MCP1/CCL2↓, *RANTES↓, *ICAM-1↓, *PGC1A↑, *NOX4↓, *Dose↝,
5038- SAS,  Rad,    Sulfasalazine, an inhibitor of the cystine-glutamate antiporter, reduces DNA damage repair and enhances radiosensitivity in murine B16F10 melanoma
- in-vivo, Melanoma, B16-F10
xCT/SLC7A11↓, ROS↑, RadioS↓, GSH↓, selectivity↑, DNArepair↓, TumCCA↑, H2O2↑, Dose↝,
4615- Se,  Rad,    Selenium as an adjuvant for modification of radiation response
- Review, Nor, NA
*antiOx↑, *radioP↑, *GSH↑, *GPx↑, *Dose↝, selectivity↑, RadioS↑,
4611- SeNPs,  Rad,    Radioprotective Effect of Selenium Nanoparticles: A Mini Review
- Review, Var, NA
*antiOx↑, *Inflam↓, *radioP↑, *ROCK1↓, *DNAdam↓, *Apoptosis↓, *RadioS↑, *Dose↝,
4612- SeNPs,  Rad,    Histopathological Evaluation of Radioprotective Effects: Selenium Nanoparticles Protect Lung Tissue from Radiation Damage
- in-vivo, Nor, NA
*radioP↑, *Inflam↓, *antiOx↑, *Dose↝, *DNAdam↓, *ROS↓, *SOD↑, *GPx↑, *Dose↝, *eff↑,
5078- SSE,  Rad,    Results from a Phase 1 Study of Sodium Selenite in Combination with Palliative Radiation Therapy in Patients with Metastatic Cancer
- Trial, Pca, NA
Half-Life↝, OS↑, Pain↓, PSA↓, GSH↓, ROS↑, selectivity↑, TumCG↓, AR↓, Dose↑, ChemoSen↑, RadioS↑,
4739- SSE,  Chemo,  Rad,    Therapeutic Benefits of Selenium in Hematological Malignancies
- Review, Var, NA
ChemoSen↑, radioP↑, QoL↑, Risk↓, *selenoP↑, TumCP↓, Inflam↓, ChemoSen↑, TumCCA↑, Apoptosis↑, angioG↓, Dose⇅, ROS↑, eff↑, Risk↓, eff∅, CSCs↓, ROS↑,
4614- SSE,  Rad,    Updates on clinical studies of selenium supplementation in radiotherapy
- Review, Nor, NA
*toxicity∅, Risk↓, *selenoP↑, *ROS↓, *DNAdam↓, *QoL↑, *radioP↑, *Dose↝,

Showing Research Papers: 1 to 24 of 24

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 24

Pathway results for Effect on Cancer / Diseased Cells:


NA, unassigned(tgid=0) ⓘ

CR↑, 1,   LC↑, 1,   NA↑, 1,   NLR↓, 1,  

Redox & Oxidative Stress(tgid=1) ⓘ

GSH↓, 2,   H2O2↑, 1,   ROS↑, 7,   TrxR↓, 1,   xCT/SLC7A11↓, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

12LOX↓, 1,  

Cell Death(tgid=5) ⓘ

Apoptosis↑, 1,   TumCD↑, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

other↝, 1,  

Protein Folding & ER Stress(tgid=8) ⓘ

HSP70/HSPA5↑, 1,  

DNA Damage & Repair(tgid=10) ⓘ

BRCA2↓, 1,   DNAdam↑, 1,   DNArepair↓, 4,   cl‑PARP↑, 1,   γH2AX↑, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

TumCCA↑, 2,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

CSCs↓, 1,   ERK↑, 1,   TumCG↓, 2,  

Migration(tgid=13) ⓘ

TumCP↓, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG↓, 1,   EPR↑, 1,   Hypoxia↓, 3,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

CRP↓, 1,   IL6↓, 1,   Imm↑, 3,   Inflam↓, 2,   MCP1/CCL2↓, 1,   PSA↓, 1,   RANTES↓, 1,  

Cellular Microenvironment(tgid=17) ⓘ

pH↝, 1,   e-pH↓, 1,  

Hormonal & Nuclear Receptors(tgid=20) ⓘ

AR↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

ChemoSen↑, 4,   Dose↓, 1,   Dose↑, 3,   Dose⇅, 1,   Dose↝, 15,   Dose∅, 1,   eff↓, 1,   eff↑, 6,   eff∅, 1,   Half-Life↝, 1,   RadioS?, 1,   RadioS↓, 1,   RadioS↑, 11,   selectivity↑, 7,  

Clinical Biomarkers(tgid=22) ⓘ

AR↓, 1,   BloodF↑, 4,   CRP↓, 1,   IL6↓, 1,   PSA↓, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiTum↑, 1,   AntiTum∅, 1,   OS↑, 4,   Pain↓, 3,   QoL↑, 2,   radioP↑, 6,   Risk↓, 3,   toxicity↝, 1,   TumVol↓, 1,  
Total Targets: 65

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↑, 3,   GPx↑, 2,   GSH↑, 1,   NOX4↓, 1,   ROS↓, 4,   selenoP↑, 2,   SOD↑, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

PGC1A↑, 1,  

Cell Death(tgid=5) ⓘ

Apoptosis↓, 1,  

DNA Damage & Repair(tgid=10) ⓘ

DNAdam↓, 3,  

Migration(tgid=13) ⓘ

Rho↓, 1,   ROCK1↓, 2,  

Barriers & Transport(tgid=15) ⓘ

IBI↑, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

ICAM-1↓, 1,   Inflam↓, 3,   MCP1/CCL2↓, 1,   p‑NF-kB↓, 1,   RANTES↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

Dose↝, 6,   eff↑, 1,   RadioS↑, 1,  

Functional Outcomes(tgid=23) ⓘ

QoL↑, 1,   radioP↑, 5,   toxicity↓, 2,   toxicity∅, 1,  
Total Targets: 25

Scientific Paper Hit Count for: Dose, Dosage
24 Radiotherapy/Radiation
7 Hyperthermia
3 Selenite (Sodium)
2 Hydrogen Gas
2 Chemotherapy
2 Selenium NanoParticles
1 Silver-NanoParticles
1 Aloe anthraquinones
1 Baicalein
1 Butyrate
1 Curcumin
1 Gold NanoParticles
1 Vitamin C (Ascorbic Acid)
1 immunotherapy
1 cetuximab
1 Rosmarinic acid
1 Sulfasalazine
1 Selenium
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:201  Target#:1114  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page